@article{c3bfc0c058d14870bf386dc2d9442c29,
title = "DNA-affibody nanoparticle delivery system for cisplatin-based breast cancer chemotherapy",
abstract = "Cisplatin is the most widely used anticancer drug, but its side effects limit the maximum systemic dose. To circumvent the side effects, a DNA tetrahedron-affibody nanoparticle was prepared by combination of a DNA chain with cisplatin via interstrand crosslinks or adducts. Each nanocarrier can bind ∼68 molecules of cisplatin. This cisplatin nanoparticle exhibited high selectivity and inhibition for breast cancer HER2 overexpressing cells BT474 and lower toxicity in MCF-7 cells with low HER2 expression. The nano-drug inhibited the growth of BT474 cells by 94.57% at 512 nM (containing 33.3 μM cisplatin), which was higher than that of cisplatin (82.9%, 33.3 μM).",
author = "Chao Zhang and Zhang, {Hong Lei} and Han, {Meng Nan} and Yang, {Xue Li} and Pei, {Chao Hong} and Xu, {Zhi Dong} and Jie Du and Wei Li and Shengxi Chen",
note = "Funding Information: This work was financially supported by the Natural Science Foundation of Hebei Province (grant number B2016201031), the Hebei Province Science Foundation for High-level Personnel (grant number GCC2014013), and the Hebei University Science Foundation (grant number 3333112). Funding Information: This work was nancially supported by the Natural Science Foundation of Hebei Province (grant number B2016201031), the Hebei Province Science Foundation for High-level Personnel (grant number GCC2014013), and the Hebei University Science Foundation (grant number 3333112). Publisher Copyright: {\textcopyright} The Royal Society of Chemistry.",
year = "2019",
doi = "10.1039/C8RA08735K",
language = "English (US)",
volume = "9",
pages = "1982--1989",
journal = "RSC Advances",
issn = "2046-2069",
publisher = "Royal Society of Chemistry",
number = "4",
}